On June 20, Nature Reviews Cardiology published online the first treatment of bicuspid aortic stenosis by transcatheter aortic valve replacement. Led by Prof. Mao Chen of the Department of Cardiology, West China Hospital(WCH), the case has won international expert consensus.The first author of the paper is Tianyuan Xiong , an assistant researcher of WCH. Mao Chen, Bernard Prendergast ofSt. Thomas’ Hospital, London,and Dr. Darren Mylotte of theUniversity Hospital Galway, National University of Irelandare the co corresponding authors. West China Hospital is the leading unit. The publication of this article points to the internationally advanced position of transcatheter valvular interventional therapy in the Department of Cardiology of West China Hospital as well as its international influence on the treatment of bicuspid aortic stenosis.
Bicuspid aortic valve is the most common congenital heart disease in adults. Patients with bicuspid aortic stenosis are more vulnerable to complications after transcatheter aortic valve replacement (TAVR) because of their anatomical particularity, so they are regarded as a challenging anatomical type of TAVR technology. However, among the relatively young elderly patients with severe aortic stenosis, the bicuspid aortic valve can account for half. How to improve the therapeutic effect of TAVR for patients bicuspid aortic stenosis has become a hot topic in the world. “---To date, patients with BAV have been excluded from major randomized trials of TAVI owing to anatomical considerations. As a consequence, BAV has been a relative contraindication to the use of TAVI in international guidelines. Although clinical experience and observational data are accumulating, BAV presents numerous anatomical challenges for successful TAVI, despite advances in device design. Furthermore, in those with BAV, substantial geographical variation exists in patient characteristics, clinical approach and procedural strategy. Therefore, in this Roadmap article, we summarize the existing evidence and provide consensus recommendations from an international group of experts on the application of TAVI in patients with BAV in advance of the anticipated growth in the use of this procedure in this challenging cohort of patients.” (Abstract)
As the first consensus recommendations in the field of interventional therapy of heart valve disease led by a Chinese team, the Roadmap article has laid the foundation for the voice of China's clinical practice and academic development in this field.
https://www.nature.com/articles/s41569-022-00734-5
